Welcome : Guest

Redhill Biopharma Ltd. (Israel) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Redhill Biopharma Ltd., which is principally involved in Biopharmaceuticals Business. Illustrated with 71 tables, the report showcases the company's recent news stories and events, key markets and market position as against its competitors operating in the industry.

Code: PCP-65256
Price: $3500
Company Type: Public
Pages: 74
Date: November 2016
Market Data Tables: 71

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Biopharmaceuticals......3
Table 1: Biopharmaceuticals Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Norditropin, NovoSeven, Turoctocog Alpha, and Others......3
Gastrointestinal Drugs......4
Table 2: Gastrointestinal Market Worldwide (2015) in US$ Million......4
Table 3: Gastrointestinal Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for H2 Blockers, Proton Pump Inhibitors, and Others......5
Multiple Sclerosis......6
Table 4: Multiple Sclerosis Disease Occurrence by Type Worldwide (2015) - Percentage Breakdown by Volume for Begin MS, Primary Progressive MS, Relapsing-Remiting MS, and Secondary Progressive MS......6
Table 5: Multiple Sclerosis Patient Care Expenditure by Category Worldwide (2015) - Percentage Breakdown by Value for Adaptations, Ambulatory Care, Disease Modifying Drugs, Early Retirement, Hospital Inpatient Care, Informal Care, Prescription and OTC Drugs, Services, Sick-leave and Redused Working Time, and Tests......7
Table 6: Relapsing-Remitting Multiple Sclerosis (RRMS) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union (EU), US, Rest of World (RoW)......8
Table 7: No. of Tcelna (Imilecleucel-T) Secondary Progressive Multiple Sclerosis Patients by Category in the US (2015) - Percentage Breakdown for Primary Progressive MS Patients, Relapsing-Remitting MS Patients, and Secondary-Progressive MS Patients......9
Central Nervous System (CNS) Drugs......10
Table 8: Central Nervous System (CNS) Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Depression, Epilepsy, Narcotic Analgesics, Non-Narcotic Analgesics, Psychotic Disorders and Others......10
Table 9: Central Nervous System Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Anti-Migraine, Antipsychotics, Newer Antidepressants, Older Antidepressants, SNRI's, SSRI’s, Tranquilizers, and Others......11
Migraine Drugs......12
Table 10: Migraine Drugs Market by Category in the US (2015) - Percentage Share Breakdown by Prescriptions for Amerge Generic (Naratriptan), Imitrex Generic (Sumatriptan), Maxalt Generic (Rizatriptan), Relpax (Pfizer), and Zomig Generic (Zolmitriptan)......12
Cancer......13
Table 11: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......13
Table 12: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......14
Table 13: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......15
Table 14: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......16
Table 15: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......17
Table 16: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......18
Table 17: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......19
Table 18: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......20
Table 19: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......21
Table 20: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......22
Table 21: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......23
Table 22: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......24
Table 23: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......25
Table 24: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......26
Bladder Cancer......27
Table 25: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......27
Breast Cancer......28
Table 26: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......28
Cervical Cancer......29
Table 27: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......29
Table 28: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......30
Colorectal Cancer......31
Table 29: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......31
Hematological Cancer......32
Table 30: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......32
Invasive Breast Cancer......33
Table 31: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......33
Table 32: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......34
Primary Liver Cancer......35
Table 33: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......35
Skin Cancer......36
Table 34: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......36
Cancer in Stage 3/4......37
Table 35: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......37
Solid Cancer Tumor Patients......38
Table 36: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......38
Cancer-Associated Mucositis......39
Table 37: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......39
Cancer Drugs......40
Table 38: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......40
Chronic Lymphocytic Leukemia (CLL)......41
Table 39: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......41
Table 40: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......42
Table 41: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......43
Chronic Myelogenous Leukemia (CML)......44
Table 42: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......44
Cutaneous Melanoma......45
Table 43: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......45
Ocular Melanoma......46
Table 44: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......46
Female Mortality......47
Table 45: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......47
Male Mortality......48
Table 46: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......48
Nausea and Vomiting Associated With Cancer Chemotherapy......49
Table 47: Nausea and Vomiting Associated With Cancer Chemotherapy Market by Drug in European Union (2015) - Percentage Share Breakdown by Value for Aprepitant (Emend), Netupitant (Akynzeo), and Rolapitant (Varubi)......49
Multiple Myeloma......50
Table 48: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......50
Table 49: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......51
Non Small Cell Lung Cancer Patients......52
Table 50: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......52
Biopharmaceuticals......53
Table 51: Market Shares of Leading Biopharmaceutical Companies Worldwide (2014) - Percentage Breakdown by Volume (Installed Capacity) for Amgen Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd., Lonza Group Ltd., Pfizer, Inc., Sanofi S.A., and Others......53
Table 52: Market Shares of Leading Biopharmaceutical Companies in the US (2015) - Percentage Market Share Breakdown by Value for Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals, Inc., Celgene Corporation, Gilead Sciences, Inc., Incyte, Corporation, Isis Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Others......54
Gastrointestinal Drugs......55
Table 53: Market Shares of Leading Gastrointestinal, Ulcer Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Pfizer, Inc., and Others......55
Table 54: Market Shares of Leading Gastrointestinal Medicine Manufacturers by Value Sales in India (2015) - Percentage Breakdown for Torrent Pharmaceuticals Ltd., and Others......56
Table 55: Market Shares of Leading Gastrointestinal (GI) Remedies Manufacturers for Over-the-Counter (OTC) Sector in the US (2015) - Percentage Breakdown by Value for GlaxoSmithKline Pharmaceuticals Limited, Johnson & Johnson Private Limited, Novartis Consumer Health, Inc., Prestige Brands Holdings, Inc., Procter & Gamble Co., Private-Label and Others......57
Table 56: Market Shares of Leading Gastrointestinal Medicine Manufacturers by Value Sales in the US (2015) - Percentage Share Breakdown for Procter & Gamble Co., and Others......58
Table 57: Market Shares of Leading Gastrointestinal Medicine Manufacturers by Volume Sales in the US (2015) - Percentage Share Breakdown for Procter & Gamble Co., and Others......59
Multiple Sclerosis......60
Table 58: Market Shares of Leading Multiple Sclerosis Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Biogen Idec, Novartis AG, Sanofi S.A., and Others......60
Table 59: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by No. of Patients for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......61
Table 60: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by Value for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......62
Central Nervous System (CNS) Medicines......63
Table 61: Market Shares of Leading Central Nervous System Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc (AZN), Bristol-Myers Squibb Company (BMY), Eli Lilly And Co (LLY), GlaxoSmithKline Plc (GSK), Johnson & Johnson, Merck & Co., Inc. (MRK), Novartis AG (NVS), Pfizer, Inc. (PFE), Shire Plc (SHPGY), and Others......63
Table 62: Market Shares of Leading Central Nervous System (CNS) Medicine Manufacturers by Value Sales in India (2015) - Percentage Breakdown for Torrent Pharmaceuticals Ltd., and Others......64
Cancer Drugs......65
Table 63: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......65
Table 64: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......66
Table 65: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......67
Table 66: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......68
Table 67: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......69
Breast Cancer Drugs......70
Table 68: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......70
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......71
Table 69: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......71
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......72
Table 70: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Other......72
Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL)......73
Table 71: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......73